AstraZeneca Pharma India receives permission for Dapagliflozin tablets

AstraZeneca Pharma India Ltd has received an Import and Market permission in Form CT-20 from the CDSCO , Directorate General of Health Services, Government of India for Dapagliflozin i.e., Forxiga® tablets of 10 mg - additional indication.

Related Keywords

India ,Dapagliflozin Forxiga ,Health Services ,Astrazeneca Pharma India ,Central Drugs Standard Control Organisation ,Zeneca Pharma India Limited ,Subsequent New Drug Approval ,Directorate General ,Astrazeneca Pharma India Limited ,Astrazenecapharmaindia ,Ine203a01020 ,Pharmaceuticals ,Permission ,Cdsco ,Dapagliflozin ,Forxiga ,